Urine evaluation recommended for recurrent stone formers

The UroRisk Diagnostic Profile from Mission Pharmacal is available forurine metabolic evaluation of renal stone disease. This test is recommendedfor initial and recurrent stone formers and those who do not test positivefor urinary tract infection. UroRisk is a semi-comprehensive evaluationthat measures nine risk factors for stone formation, the company says. Testresults are reported on an easy-to-read graphic display.

Related Videos

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.

December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.

Related Content

Advertisement

December 20th 2024

FDA reports Urgent Field Safety Notice on mini PCNL sheath

Hannah Clarke

The alert was issued to clarify that the devices should not be used for suction and irrigation.

November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

December 20th 2024

Investigators identify potential dual targets in prostate cancer

Hannah Clarke

“Our findings highlight the coordinated interplay between GCN2 and p53 regulation during nutrient stress and provide insight into how they could be targeted in developing new therapeutic strategies for [prostate cancer]," write the authors.

November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff

In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.

December 19th 2024

FDA greenlights phase 1/2 trial of gene editing therapy for primary hyperoxaluria 1

Hannah Clarke

The redePHine trial is expected to launch in the first half of 2025.

December 18th 2024

NCCN reaffirms Prolaris’ prognostic value in prostate cancer

Hannah Clarke

The inclusion of the test is supported by more than 25 studies demonstrating its clinical utility, including 2 studies published earlier this year.